[1] |
Ma NF, Hu L, Fung JM, et al. Isolation and characterization of a novel oncogene, amplified in liver cancer 1, within a commonly amplified region at 1q21 in hepatocellular carcinoma[J]. Hepatology, 2008, 47(2): 503-510.
|
[2] |
Wu J, Zong Y, Fei X, et al. Presence of CHD1L over-expression is associated with aggressive tumor biology and is a novel prognostic biomarker for patient survival in human breast cancer[J]. PLoS One, 2014, 9(8): e98673.
|
[3] |
Su Z, Zhao J, Xian G, et al. CHD1L is a novel independent prognostic factor for gastric cancer[J]. Clin Transl Oncol, 2014, 16(8): 702-707.
|
[4] |
Ji X, Li J, Zhu L, et al. CHD1L promotes tumor progression and predicts survival in colorectal carcinoma[J]. J Surg Res, 2013, 185(1): 84-91.
|
[5] |
He WP, Zhou J, Cai MY, et al. CHD1L Protein is overexpressed in human ovarian carcinomas and is a novel predictive biomarker for patients survival[J]. BMC Cancer, 2012, 12(1): 1-8.
|
[6] |
郑小梅, 张晓立, 于建东, 等. CRISPR-Cas9介导的基因组编辑技术的研究进展[J]. 生物技术进展, 2015, 5(1): 1-9.
|
[7] |
Pelletier S, Gingras S, Green DR. Mouse genome engineeringvia CRISPR-Cas9 for study of immune function[J]. Immunity, 2015, 42(1): 18-27.
|
[8] |
Gossen M, Bujard H. Tight control of gene expression in mammalian cells by tetracycline-responsive promoters[J]. Proc Natl Acad Sci U S A, 1992, 89(12): 5547-5551.
|
[9] |
Wang T, Wei JJ, Sabatini DM, et al. Genetic screens in human cells using the CRISPR-Cas9 system[J]. Science, 2014, 343(6166): 80-84.
|
[10] |
Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma[J]. Lancet, 2012, 379(9822): 1245-1255.
|
[11] |
Tang KH, Ma S, Lee TK, et al. Chan YP CD133(+) liver tumor-initiating cells promote tumor angiogenesis, growth, and self-renewal through neurotensin/interleukin-8/CXCL1 signaling[J]. Hepatology, 2012, 55(3): 807-820.
|
[12] |
Yang ZF, Ho DW, Nq MN, et al. Significance of CD90+ cancer stem cells in human liver cancer[J]. Cancell cell, 2008, 13(2): 153-166.
|
[13] |
Yang W, Wang C, Lin Y, et al. OV6+ tumor-initiating cells contribute to tumor progression and invasion in human hepatocellular carcinoma[J]. J Hepatol, 2012, 57(3): 613-620.
|
[14] |
Lee TK, Cheung VC, Ng IO. Liver tumor-initiating cells as a therapeutic target for hepatocellular carcinoma[J]. Cancer Lett, 2013, 338(1): 101-109.
|
[15] |
Snider AC, Leong D, Wang QT, et al. The chromatin remodeling factor Chd1l is required in the preimplantation embryo[J]. Biol Open, 2013, 2(2): 121-131.
|
[16] |
Dou D, Zhao H, Li Z, et al. CHD1L promotes neuronal differentiation in human embryonic stem cells by upregulatingPAX6[J]. Stem Cells Dev, 2017, 26(22): 1626-1636.
|
[17] |
Liu SS, Bai YS, Feng L, et al. Identification of CHD1L as an important regulator for spermatogonial stem cell survival and self-renewal[J]. Stem Cells Int, 2016, 2016: e4069543.
|
[18] |
Liu M, Chen L, Ma NF, et al. CHD1L promotes lineage reversion of hepatocellular carcinoma through opening chromatin for key developmental transcription factors[J]. Hepatology, 2016, 63(5): 1544-1559.
|
[19] |
He LR, Ma NF, Chen JW, et al. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival[J]. Oncotarget, 2015, 6(31): 31181-31190.
|
[20] |
Liu SS, Maguire EM, Bai YS, et al. A novel regulatory axis, CHD1L-microRNA 486-matrix metalloproteinase 2, controls spermatogonial stem cell properties[J]. Mol Cell Biol, 2019, 39(4): e00357-18.
|
[21] |
Slaymaker IM, Gao L, Zetsche B, et al. Rationally engineered Cas9 nucleases with improved specificity[J]. Science, 2016, 351(6268):84-88.
|
[22] |
Gajbhiye V, Escalante L, Chen G, et al. Drug-loaded nanoparticles induce gene expression in human pluripotent stem cell derivatives[J]. Nanoscale, 2014, 6(1): 521-531.
|